AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03191071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin will be measured using a rapid point-of-care test
Study NCT03191071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
Study NCT03191071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Naso-pharyngeal swab and sputum culture
Description: A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
Study NCT03191071 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Naso-pharyngeal swab and sputum culture
Description: A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
Study NCT03990636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metil 5-aminolevulinate
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
Study NCT03990636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metil 5-aminolevulinate
Description: Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
Study NCT03672799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Planning Consult (RPC)
Description: Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC.
Study NCT03672799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Planning Consult (RPC)
Description: Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC.
Study NCT03672799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control (WLC)
Description: Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC.
Study NCT02864823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perichondrium Autografts
Description: Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
Study NCT01410864 — intervention group
Intervention type: DEVICE
Intervention: DuraSeal Exact Spine Sealant System
Description: DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
Study NCT01410864 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Devices or drugs used to seal the dura (other than DuraSeal)
Study NCT02118259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Before-after study
Description: The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time.
Study NCT01146028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg
Study NCT01146028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine HCl Tablets 4 mg
Study NCT02412254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best practices hearing rehabilitative treatment
Description: Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
Study NCT02412254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Successful aging intervention
Description: One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
Study NCT03299725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloidal bismuth sub-citrate
Description: colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
Study NCT03385551 — intervention group
Intervention type: DRUG
Intervention: Estradiol
Description: Estradiol or Promestriene depending on the arm
Study NCT02450422 — intervention group
Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.
Study NCT02450422 — intervention group
Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study NCT00869973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
Study NCT00869973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
Study NCT01283022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT01538394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Study NCT01538394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Study NCT01538394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Study NCT01538394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (nicotine patches)
Study NCT03503734 — intervention group
Intervention type: BEHAVIORAL
Intervention: Integrated headache care
Description: The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions.
Study NCT01522131 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bioresorbable membrane alonewill be used for regeneration of the periodontium(control)
Description: bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
Study NCT01522131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioresorbable membrane alonewill be used for regeneration of the periodontium(control)
Description: bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
Study NCT03103685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
Study NCT03103685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
Study NCT02063581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Capsule)
Description: Orally administered single dose of Ipatasertib formulated as a capsule.
Study NCT02063581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib (Tablet)
Description: Orally administered single dose of Ipatasertib formulated as a tablet.
Study NCT00607464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrap
Description: Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
Study NCT02612506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Study NCT02612506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Study NCT06376305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EndoBarrier
Description: During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires.
Study NCT04045847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD147-CART
Description: Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
Study NCT03510429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postoperative Nutritional Supplement
Description: Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
Study NCT03510429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine post-op care
Description: Routine post-operative care
Study NCT03850691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin: All Patients
Description: Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)
Study NCT03850691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab: Cohort 1 (Cutaneous)
Description: Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study
Study NCT03850691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab: Cohort 2 (Ocular)
Description: Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study
Study NCT03850691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab: Cohort 2 (Ocular)
Description: Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29
Study NCT04618809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic Session
Description: This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
Study NCT04618809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.
Description: * The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded.
Study NCT01281943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Description: Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle
Study NCT01065298 — intervention group
Intervention type: BIOLOGICAL
Intervention: stem cell transplantation
Description: Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
Study NCT04150120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-health device with application
Description: In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
Study NCT03706716 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: decision aid developed for pelvic organ prolapse
Description: Conversation based upon the inter face in the Electronic patient journal.
Study NCT04442698 — intervention group
Intervention type: PROCEDURE
Intervention: Mini-Gastric Bypass Original Technique
Description: Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
Study NCT04260568 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
Study NCT03873311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine, HAG Regimen
Description: Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
Study NCT03873311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacytidine
Description: Azacytidine 75mg/m2 QD for 7 days.
Study NCT02974803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
Study NCT02974803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 2 mg once daily until progression or unaccepted toxicity.
Study NCT01964716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
Study NCT01964716 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
Study NCT01133496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets, 70 mg
Description: Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
Study NCT01133496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium Tablets, 70 mg
Description: Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
Study NCT04337476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention
Description: Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
Study NCT06265571 — intervention group
Intervention type: OTHER
Intervention: perineural injection
Description: perineural injection of local anesthestetic for postoperative pain management
Study NCT04213833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol Injection [Diprivan]
Description: patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
Study NCT04213833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine [Precedex]
Description: patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
Study NCT04213833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palatable Lidocaine Topical Gel
Description: 15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
Study NCT01782768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation
Description: the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
Study NCT00947323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: simvastatin 20 daily for six months.